Literature DB >> 8615179

Involvement of serotonin in clinical features of Parkinson's disease and complications of L-DOPA therapy.

E Melamed1, J Zoldan, G Friedberg, I Ziv, A Weizmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8615179

Source DB:  PubMed          Journal:  Adv Neurol        ISSN： 0091-3952


× No keyword cloud information.
  10 in total

1.  Changes in sleep electroencephalogram and nocturnal hormone secretion after administration of the antidyskinetic agent sarizotan in healthy young male volunteers.

Authors:  Heike E Kuenzel; Axel Steiger; Katja Held; Irina A Antonijevic; Ralf-Michael Frieboes; Harald Murck
Journal:  Psychopharmacology (Berl)       Date:  2005-02-17       Impact factor: 4.530

Review 2.  Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain.

Authors:  S Navailles; M Lagière; A Contini; P De Deurwaerdère
Journal:  ACS Chem Neurosci       Date:  2013-04-15       Impact factor: 4.418

3.  Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders.

Authors:  R P Iacono; S M Kuniyoshi; J R Ahlman; G J Zimmerman; G Maeda; R D Pearlstein
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 4.  Contribution of serotonergic transmission to the motor and cognitive effects of high-frequency stimulation of the subthalamic nucleus or levodopa in Parkinson's disease.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Mol Neurobiol       Date:  2012-01-06       Impact factor: 5.590

Review 5.  Presynaptic control of serotonin on striatal dopamine function.

Authors:  Sylvia Navailles; Philippe De Deurwaerdère
Journal:  Psychopharmacology (Berl)       Date:  2010-10-16       Impact factor: 4.530

6.  Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats.

Authors:  P De Deurwaèrdere; M F Chesselet
Journal:  J Neurosci       Date:  2000-07-01       Impact factor: 6.167

Review 7.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

8.  Influence of repeated levodopa administration on rabbit striatal serotonin metabolism, and comparison between striatal and CSF alterations.

Authors:  D A Loeffler; P A LeWitt; P L Juneau; D M Camp; A J DeMaggio; M K Havaich; P E Milbury; W R Matson
Journal:  Neurochem Res       Date:  1998-12       Impact factor: 3.996

Review 9.  Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases.

Authors:  Giuseppe Di Giovanni; Dubravka Svob Strac; Montse Sole; Mercedes Unzeta; Keith F Tipton; Dorotea Mück-Šeler; Irene Bolea; Laura Della Corte; Matea Nikolac Perkovic; Nela Pivac; Ilse J Smolders; Anna Stasiak; Wieslawa A Fogel; Philippe De Deurwaerdère
Journal:  Front Neurosci       Date:  2016-11-24       Impact factor: 4.677

10.  Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.

Authors:  Agnieszka Ciesielska; Lluis Samaranch; Waldy San Sebastian; Dennis W Dickson; Samuel Goldman; John Forsayeth; Krystof S Bankiewicz
Journal:  PLoS One       Date:  2017-02-06       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.